ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

Core Insights - ALX Oncology will host a webcast on May 20, 2025, to provide updates on ALX2004, a potentially first-in-class antibody-drug conjugate designed to treat cancer [1][3] - ALX2004 is developed in-house and utilizes a proprietary topoisomerase I inhibitor payload platform, targeting EGFR-expressing tumors to enhance anti-tumor activity [2] Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment, with its lead candidate evorpacept currently in multiple clinical trials [4] - ALX2004 is expected to enter Phase 1 trials in mid-2025, showcasing a differentiated mechanism of action [4]